陈建军，教授，博士生导师，青年海外高层次人才，南方医科大学药学院药物化学系主任、药物化学教学团队负责人、药物设计与发现研究创新中心主任。主要研究方向为肿瘤免疫小分子调节剂的发现。主持美国NIH SC3、中国国自然面上、中组部青年海外高层次人才项目、广东省科技厅国际合作等多项国家/省级课题。在Signal Transduct Target Ther, Acta Pharm Sin B、J Med Chem、Pharmacol Res等本领域一流杂志发表SCI论文110余篇（通讯/一作80篇，IF>10分4篇），包括17篇药物化学/新药发现顶刊J Med Chem；文章总引用约5000，H指数为40；2021-2022连续两年入选爱思维尔/斯坦福全球前2%顶尖科学家。申请和授权30多项中国及国外专利，转让5项（3项临床试验、两项临床前）。担任J Med Chem顾问编委(Editorial Advisory Board Member)、药学学报（APSB）中英文青年编委、广东省药监局药审中心评审专家、广东省药学会药物化学委员会副主任委员、广东省药理学会-药物筛选与评价专业委员会常务委员等学术兼职。主导发现：原创小分子Sabizabulin（VERU-111），在美国进行2项临床III期、1项临床II期试验；其作为全球首个口服抗新冠重症小分子药物已向美国/欧盟/英国/澳大利亚等国提交“紧急使用授权/EUA”上市申请。2个候选抗癌药物在中国进入临床前研究；16个用于生物医药研究的工具药物授权给MCE、陶素/TargetMol、Medkoo、InvivoChem等公司进行全球销售。

肿瘤免疫/炎症免疫小分子调节剂的设计、合成及生物活性研究

(1) Binbin Cheng#, Wei Wang#, Ting Liu, Hao Cao, Wei Pan, Yao Xiao, Shuwen Liu*, Jianjun Chen*. Bifunctional Small Molecules Targeting PD-L1/CXCL12 as Dual Immunotherapy for Cancer Treatment. Signal Transduct Target Ther. (STTT)，2023 Mar 1;8(1):91. (IF=38.104, 1区).

(2) Xiaopeng Peng#, Yichang Ren#, Wanyi Pan, Jin Liu, Jianjun Chen*. Discovery of Novel Acridane-based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects. J Med Chem, 2023 Jan 12, 66(1):627-640. (IF=8.039, 小类1区).

(3) Yinrong Wu#, Zichao Yang#, Kui Cheng*, Huichang Bi*, Jianjun Chen*. Small molecule-based immunomodulators for cancer therapy. Acta Pharmaceutica Sinica B, 2022 Dec;12(12):4287-4308 (IF=14.903, 小类1区)

(4) Xiaopeng Peng#, Wanyi Pan#, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng*, Jianjun Chen*. Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy. Pharmacol Res, 2022 Dec, 186, 106529. (IF=10.334, 小类1区)

(5) Jin Liu, Lin Yuan, Yong Ruan, Bulian Deng, Zicao Yang, Yichang Ren, Ling Li, Ting Liu, Huiting Zhao, Ruiyao Mai, Jianjun Chen*. Novel CRBN-recruiting PROTACs as Degraders of STING With In Vivo Anti-inflammatory Efficacy. J Med Chem, 2022 May 12; 65(9):6593-6611.(IF=8.039, 小类1区)

(6) Xiaopeng Peng#, Ling Li#, Jingxuan Chen#, Yichang Ren, Jin Liu, Ziwen Yu, Hao Cao, Jianjun Chen*. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. J Med Chem, 2022 Feb 10;65(3):2434-2457.(IF=8.039, 小类1区)

(7) Xiaopeng Peng#, Jingxuan Chen#, Ling Li, Zhiqiang Sun, Jin Liu, Yichang Ren, Junli Huang, Jianjun Chen*. Efficient Synthesis and Bioevaluation of Novel Dual Tubulin / Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. J Med Chem., 2021 Jun 24;64(12):8447-8473.(IF=8.039, 小类1区)

(8) Binbin Cheng, Wei Wang, Xiaoge Niu, Yichang Ren, Ting Liu, Hao Cao, Shuanghu Wang, Yingfeng Tu, Jingxuan Chen, Shuwen Liu, Xuchao Yang, Jianjun Chen*. Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. J Med Chem., 2020 Dec 24;63(24):15946-15959.(IF=8.039, 小类1区)

(9) Binbin Cheng, Yichang Ren, Wei Wang, Shuanghu Wang, Yingfeng Tu, Shuwen Liu, Jin Wang, Deying Yang, Guochao Liao, Jianjun Chen*. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction As Potential Anticancer Agents. J Med Chem, 2020 Aug 13; 63(15):8338-8358.(IF=8.039, 小类1区)

(10) Ruiyao Mai, Bulian Deng, Huiting Zhao, Ling Li, Yuyu Fang, Siming Li, Xin Deng*, Jianjun Chen*. Design, Synthesis and Bioevaluation of Novel Enzyme Triggerable Cell Penetrating Peptide (ETCPP)-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy. J Med Chem, 2022 Apr 14;65(7):5850-5865.(IF=8.039, 小类1区)

(11) Yichang Ren#, Yuxi Wang#, Gang Li#, Zherong Zhang, Lingling Ma, Binbin Cheng, Jianjun Chen*. Discovery of Novel Benzimidazole and Indazole Analogs as Tubulin Polymerization Inhibitors With Potent Anticancer Activities. J Med Chem., 2021 Apr 22;64(8):4498-4515.(IF=8.039, 小类1区)

(12) Binbin Cheng#, Yao Xiao#, Mingming Xue#, Hao Cao, Jianjun Chen*, Recent advances in the development of PD-L1 modulators: degraders, downregulators, and covalent inhibitors. J Med Chem., 2020 Dec 24; 63(24):15389-15398. (IF=8.039, 小类1区)

(13) Xiaoshuang Guo; Yuan Cheng; Xiaotian Zhao; Yanli Luo; Jianjun Chen*, Wei-En Yuan*. Advances in redox-responsive drug delivery systems of tumor microenvironment, J Nanobiotechnology, 2018 Sep 22;16(1):74. (IF=10.435, 小类1区)

(14) Jianjun Chen, Sunjoo Ahn, Jin Wang, Yan Lu, James T. Dalton, Duane D. Miller, Wei Li, “Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents”, J Med Chem., 2012, 55, 7285-7289.(IF=8.039, 小类1区) [本文首次报道的化合物已转让给美国 VeruPharm 公司, 目前在美国进行3项临床3/2期试验，分别治疗：(1) 晚期前列腺癌 (3期: NCT04844749); (2) 新型冠状病毒COVID-19所引起的严重呼吸综合症 (3期: NCT04842747，已在美国、英国、欧盟、澳大利亚等国提交紧急使用授权/EUA上市申请)；(3) 三阴性乳腺癌(2期: NCT05079360); 化合物代号: VERU-111， 正式名称：Sabizabulin].

(15) Yichang Ren#, Yuxi Wang#, Jin Liu#, Ting Liu, Lin Yuan, Chengyong Wu, Zichao Yang, Jianjun Chen*. X-ray Crystal Structure Guided Discovery of Novel Indole Analogs as Colchicine Binding Site Tubulin Inhibitors with Immune Potentiating and Antitumor Effects against Melanoma. J Med Chem, 2023 (under revision)